[8-K] ProMIS Neurosciences Inc. Reports Material Event
ProMIS Neurosciences Inc. filed a Form 8-K announcing it issued a press release reporting its financial condition and results for the three and six months ended June 30, 2025. The filing states the press release is available on the company's website under Investors/Financial Results and that a copy is furnished as Exhibit 99.1 to the report. The 8-K identifies the company as a Nasdaq-listed registrant trading as PMN on The Nasdaq Capital Market and indicates the registrant has the status of an emerging growth company.
The filing itself does not include the financial statements or numerical results; investors are directed to the press release (Exhibit 99.1) for the detailed financial figures and discussion of the companys performance for the reported periods.
ProMIS Neurosciences Inc. ha depositato un Modulo 8鈥慘 comunicando di aver emesso un comunicato stampa che riporta la sua situazione finanziaria e i risultati per i tre e i sei mesi chiusi al 30 giugno 2025. Il deposito indica che il comunicato 猫 disponibile sul sito della societ脿 nella sezione Investors/Financial Results e che una copia 猫 fornita come Exhibit 99.1 nella relazione. L'8鈥慘 identifica la societ脿 come un emittente quotato al Nasdaq, che negozia con il simbolo PMN sul Nasdaq Capital Market, e precisa che la societ脿 ha lo status di 'emerging growth company'.
Il deposito in s茅 non contiene i bilanci n茅 i dati numerici; gli investitori sono indirizzati al comunicato stampa (Exhibit 99.1) per i dettagli finanziari e la discussione delle performance relative ai periodi riportati.
ProMIS Neurosciences Inc. present贸 un Formulario 8鈥慘 anunciando que emiti贸 un comunicado de prensa en el que informa sobre su situaci贸n financiera y los resultados correspondientes a los tres y seis meses terminados el 30 de junio de 2025. El documento indica que el comunicado est谩 disponible en la web de la compa帽铆a en la secci贸n Investors/Financial Results y que una copia se adjunta como Exhibit 99.1 al informe. El 8鈥慘 identifica a la compa帽铆a como una emisora cotizada en Nasdaq que opera bajo el s铆mbolo PMN en The Nasdaq Capital Market y se帽ala que tiene la condici贸n de 'emerging growth company'.
La presentaci贸n en s铆 no incluye los estados financieros ni las cifras num茅ricas; se remite a los inversores al comunicado de prensa (Exhibit 99.1) para las cifras financieras detalladas y el an谩lisis del desempe帽o de la compa帽铆a en los periodos informados.
ProMIS Neurosciences Inc.電� Form 8鈥慘毳� 鞝滌稖頃橃棳 2025雲� 6鞗� 30鞚茧 膦呺霅� 3臧滌洈 氚� 6臧滌洈 旮瓣皠鞚� 鞛靸來儨 氚� 鞁れ爜鞚� 氤搓碃頃橂姅 氤措弰鞛愲毳� 氚滍枆頄堧嫟瓿� 瓿奠嫓頄堨姷雼堧嫟. 鞝滌稖靹滊鞐� 霐半ゴ氅� 頃措嫻 氤措弰鞛愲電� 須岇偓 鞗轨偓鞚错姼鞚� Investors/Financial Results 靹轨厴鞐愳劀 頇曥澑頃� 靾� 鞛堨溂氅�, 氤搓碃靹滌潣 Exhibit 99.1搿� 靷掣鞚� 鞝滉车霅橃柎 鞛堨姷雼堧嫟. 頃措嫻 8鈥慘電� 須岇偓毳� 雮橃姢雼�(Nasdaq)鞐� 靸侅灔霅� 霌彪旮办梾鞙茧 鞁濍硠頃橁碃 鞛堨溂氅�, 雮橃姢雼� 旌愴敿韯� 毵堨紦(The Nasdaq Capital Market)鞐愳劀 PMN鞚措澕電� 鞁臣搿� 瓯半灅霅橁碃 鞛堦碃, 霌彪旮办梾鞚� 'emerging growth company' 歆�鞙勲ゼ 氤挫湢頃橁碃 鞛堨潓鞚� 雮橅儉雰呺媹雼�.
頃措嫻 鞝滌稖靹滊 鞛愳泊鞐愲姅 鞛鞝滍憸雮� 靾橃箻臧� 韽暔霅橃柎 鞛堨 鞎婌溂氅�, 韴瀽鞛愲摛鞚� 靸侅劯頃� 鞛靾橃箻鞕� 氤搓碃旮瓣皠 靹标臣鞐� 甏�頃� 雲检潣毳� 氤措弰鞛愲(Exhibit 99.1)鞐愳劀 頇曥澑頃橂弰搿� 鞎堧偞頃橁碃 鞛堨姷雼堧嫟.
ProMIS Neurosciences Inc. a d茅pos茅 un formulaire 8鈥慘 annon莽ant la publication d'un communiqu茅 de presse faisant 茅tat de sa situation financi猫re et de ses r茅sultats pour les trois et six mois clos le 30 juin 2025. Le d茅p么t pr茅cise que le communiqu茅 est disponible sur le site de la soci茅t茅 dans la rubrique Investors/Financial Results et qu'une copie est fournie en tant qu'Exhibit 99.1 du rapport. Le 8鈥慘 identifie la soci茅t茅 comme un enregistrement cot茅 au Nasdaq, n茅goci茅 sous le sigle PMN sur le Nasdaq Capital Market, et indique que la soci茅t茅 b茅n茅ficie du statut d'芦 emerging growth company 禄.
Le d茅p么t lui鈥憁锚me n'inclut pas les 茅tats financiers ni les chiffres; les investisseurs sont renvoy茅s au communiqu茅 de presse (Exhibit 99.1) pour obtenir les d茅tails financiers et l'analyse des performances de la soci茅t茅 pour les p茅riodes concern茅es.
ProMIS Neurosciences Inc. hat ein Formular 8鈥慘 eingereicht und mitgeteilt, dass eine Pressemitteilung ver枚ffentlicht wurde, die die finanzielle Lage und die Ergebnisse f眉r die drei und sechs Monate zum 30. Juni 2025 berichtet. In der Einreichung hei脽t es, dass die Pressemitteilung auf der Website des Unternehmens unter Investors/Financial Results verf眉gbar ist und eine Kopie als Exhibit 99.1 dem Bericht beigef眉gt ist. Das 8鈥慘 f眉hrt das Unternehmen als bei Nasdaq gelisteten Registranten, der unter dem K眉rzel PMN am Nasdaq Capital Market gehandelt wird, und weist darauf hin, dass der Registrant den Status einer 'emerging growth company' hat.
Die Einreichung selbst enth盲lt keine Abschl眉sse oder numerischen Ergebnisse; Investoren werden auf die Pressemitteilung (Exhibit 99.1) verwiesen, um die detaillierten Finanzzahlen und die Darstellung der Unternehmensleistung f眉r die berichteten Zeitr盲ume einzusehen.
- None.
- None.
Insights
TL;DR: Routine earnings disclosure furnished as an exhibit; the filing contains no financial figures, so investors must read Exhibit 99.1 for results.
The Form 8-K notifies the market that ProMIS released its quarterly results via press release and furnished that release as Exhibit 99.1. Because this filing does not include the underlying numerical statements or commentary, it is a procedural disclosure confirming the availability of results rather than presenting new quantitative data within the filing itself. Market participants should review the press release on the company's Investor Relations page to evaluate revenue, net income/loss, cash position, and any commentary on operating drivers or reserves.
TL;DR: Compliance-focused filing that furnishes the press release as an exhibit and affirms public disclosure practices; no governance changes disclosed.
The company used the Form 8-K to furnish a press release reporting interim financial results and to make the release publicly accessible via its website. The filing reflects standard disclosure practice for timely distribution of material financial information and includes the exhibit reference for regulatory traceability. No executive changes, restatements, waivers, or material contracts are disclosed in this document.
ProMIS Neurosciences Inc. ha depositato un Modulo 8鈥慘 comunicando di aver emesso un comunicato stampa che riporta la sua situazione finanziaria e i risultati per i tre e i sei mesi chiusi al 30 giugno 2025. Il deposito indica che il comunicato 猫 disponibile sul sito della societ脿 nella sezione Investors/Financial Results e che una copia 猫 fornita come Exhibit 99.1 nella relazione. L'8鈥慘 identifica la societ脿 come un emittente quotato al Nasdaq, che negozia con il simbolo PMN sul Nasdaq Capital Market, e precisa che la societ脿 ha lo status di 'emerging growth company'.
Il deposito in s茅 non contiene i bilanci n茅 i dati numerici; gli investitori sono indirizzati al comunicato stampa (Exhibit 99.1) per i dettagli finanziari e la discussione delle performance relative ai periodi riportati.
ProMIS Neurosciences Inc. present贸 un Formulario 8鈥慘 anunciando que emiti贸 un comunicado de prensa en el que informa sobre su situaci贸n financiera y los resultados correspondientes a los tres y seis meses terminados el 30 de junio de 2025. El documento indica que el comunicado est谩 disponible en la web de la compa帽铆a en la secci贸n Investors/Financial Results y que una copia se adjunta como Exhibit 99.1 al informe. El 8鈥慘 identifica a la compa帽铆a como una emisora cotizada en Nasdaq que opera bajo el s铆mbolo PMN en The Nasdaq Capital Market y se帽ala que tiene la condici贸n de 'emerging growth company'.
La presentaci贸n en s铆 no incluye los estados financieros ni las cifras num茅ricas; se remite a los inversores al comunicado de prensa (Exhibit 99.1) para las cifras financieras detalladas y el an谩lisis del desempe帽o de la compa帽铆a en los periodos informados.
ProMIS Neurosciences Inc.電� Form 8鈥慘毳� 鞝滌稖頃橃棳 2025雲� 6鞗� 30鞚茧 膦呺霅� 3臧滌洈 氚� 6臧滌洈 旮瓣皠鞚� 鞛靸來儨 氚� 鞁れ爜鞚� 氤搓碃頃橂姅 氤措弰鞛愲毳� 氚滍枆頄堧嫟瓿� 瓿奠嫓頄堨姷雼堧嫟. 鞝滌稖靹滊鞐� 霐半ゴ氅� 頃措嫻 氤措弰鞛愲電� 須岇偓 鞗轨偓鞚错姼鞚� Investors/Financial Results 靹轨厴鞐愳劀 頇曥澑頃� 靾� 鞛堨溂氅�, 氤搓碃靹滌潣 Exhibit 99.1搿� 靷掣鞚� 鞝滉车霅橃柎 鞛堨姷雼堧嫟. 頃措嫻 8鈥慘電� 須岇偓毳� 雮橃姢雼�(Nasdaq)鞐� 靸侅灔霅� 霌彪旮办梾鞙茧 鞁濍硠頃橁碃 鞛堨溂氅�, 雮橃姢雼� 旌愴敿韯� 毵堨紦(The Nasdaq Capital Market)鞐愳劀 PMN鞚措澕電� 鞁臣搿� 瓯半灅霅橁碃 鞛堦碃, 霌彪旮办梾鞚� 'emerging growth company' 歆�鞙勲ゼ 氤挫湢頃橁碃 鞛堨潓鞚� 雮橅儉雰呺媹雼�.
頃措嫻 鞝滌稖靹滊 鞛愳泊鞐愲姅 鞛鞝滍憸雮� 靾橃箻臧� 韽暔霅橃柎 鞛堨 鞎婌溂氅�, 韴瀽鞛愲摛鞚� 靸侅劯頃� 鞛靾橃箻鞕� 氤搓碃旮瓣皠 靹标臣鞐� 甏�頃� 雲检潣毳� 氤措弰鞛愲(Exhibit 99.1)鞐愳劀 頇曥澑頃橂弰搿� 鞎堧偞頃橁碃 鞛堨姷雼堧嫟.
ProMIS Neurosciences Inc. a d茅pos茅 un formulaire 8鈥慘 annon莽ant la publication d'un communiqu茅 de presse faisant 茅tat de sa situation financi猫re et de ses r茅sultats pour les trois et six mois clos le 30 juin 2025. Le d茅p么t pr茅cise que le communiqu茅 est disponible sur le site de la soci茅t茅 dans la rubrique Investors/Financial Results et qu'une copie est fournie en tant qu'Exhibit 99.1 du rapport. Le 8鈥慘 identifie la soci茅t茅 comme un enregistrement cot茅 au Nasdaq, n茅goci茅 sous le sigle PMN sur le Nasdaq Capital Market, et indique que la soci茅t茅 b茅n茅ficie du statut d'芦 emerging growth company 禄.
Le d茅p么t lui鈥憁锚me n'inclut pas les 茅tats financiers ni les chiffres; les investisseurs sont renvoy茅s au communiqu茅 de presse (Exhibit 99.1) pour obtenir les d茅tails financiers et l'analyse des performances de la soci茅t茅 pour les p茅riodes concern茅es.
ProMIS Neurosciences Inc. hat ein Formular 8鈥慘 eingereicht und mitgeteilt, dass eine Pressemitteilung ver枚ffentlicht wurde, die die finanzielle Lage und die Ergebnisse f眉r die drei und sechs Monate zum 30. Juni 2025 berichtet. In der Einreichung hei脽t es, dass die Pressemitteilung auf der Website des Unternehmens unter Investors/Financial Results verf眉gbar ist und eine Kopie als Exhibit 99.1 dem Bericht beigef眉gt ist. Das 8鈥慘 f眉hrt das Unternehmen als bei Nasdaq gelisteten Registranten, der unter dem K眉rzel PMN am Nasdaq Capital Market gehandelt wird, und weist darauf hin, dass der Registrant den Status einer 'emerging growth company' hat.
Die Einreichung selbst enth盲lt keine Abschl眉sse oder numerischen Ergebnisse; Investoren werden auf die Pressemitteilung (Exhibit 99.1) verwiesen, um die detaillierten Finanzzahlen und die Darstellung der Unternehmensleistung f眉r die berichteten Zeitr盲ume einzusehen.
FAQ
Where can I find ProMIS Neurosciences (PMN) Q2 2025 results?
Does the Form 8-K include numerical financial statements for PMN?
What exchange and ticker does ProMIS Neurosciences use?
Is ProMIS Neurosciences identified as an emerging growth company in the filing?
Which exhibit contains the press release referenced in the 8-K?
